Long-term efficacy of rasagiline in early Parkinson's disease

Mark F. Lew, Robert A. Hauser, Howard I. Hurtig, William G. Ondo, Joanne Wojcieszek, Tamar Goren, Cheryl J. Fitzer-Attas

Research output: Contribution to journalArticlepeer-review

26 Scopus citations


This study was designed to follow the long-term efficacy, safety, and tolerability of rasagiline for Parkinson's disease (PD) with data collected from all patients who had ever taken rasagiline during the 12-month TEMPO monotherapy trial (N=398) and subsequent open-label extension. Patients were followed for up to 6.5 years with a mean of 3.5 ± 2.1 years. After 12 months, additional PD medications were added as required. Of patients remaining in the trial at 2 years, 46% were maintained on rasagiline monotherapy. The majority of patients received a dopamine agonist prior to levodopa as the first additional dopaminergic agent. Analysis using a Kaplan-Meier method indicated that by 5.4 years only 25 of patients progressed to Hoehn & Yahr stage III. Rasagiline was well tolerated, with 11.3% of patients (45/398) withdrawing because of an adverse event. Rasagiline therapy for PD was effective, well tolerated, and safe in this long-term trial.

Original languageEnglish (US)
Pages (from-to)404-408
Number of pages5
JournalInternational Journal of Neuroscience
Issue number6
StatePublished - May 1 2010


  • Dopamine agonists
  • Efficacy
  • Levodopa
  • Long-term
  • Monotherapy
  • Rasagiline

ASJC Scopus subject areas

  • Neuroscience(all)


Dive into the research topics of 'Long-term efficacy of rasagiline in early Parkinson's disease'. Together they form a unique fingerprint.

Cite this